Inquire Today!

APOE2 - Model 1547


C57BL/6 Background

Model Number Zygosity Nomenclature
1547-F Homozygous
B6.129P2-Apoetm1(APOE*2)Mae N9
1547-M Homozygous
B6.129P2-Apoetm1(APOE*2)Mae N9
  • Description
  • Health Report

Model Description

  • Homozygous for a human APOE2 gene targeted replacement of the endogenous mouse Apoe gene
  • Expresses human apoliprotein E2 isoform under the control of the murine Apoe regulatory sequences
  • ApoE is a plasma protein involved in cholesterol transport, with three human isoforms (E2, E3, and E4) that have been associated with atherosclerosis and Alzheimer's Disease (AD)
  • E2 is the least common isoform in the human population
  • In humans, the E2 allele decreases the risk and delays onset of AD, but increases the risk of type III hyperlipoproteinemia
  • Develops hyperlipoproteinemia with elevated plasma cholesterol and triglyceride levels, decreased clearance of vLDL particles, and spontaneous atherosclerotic plaques on a normal diet, exacerbated by a high fat diet
  • Useful for studying the role of human APOE polymorphism in atherosclerosis, lipid metabolism and Alzheimer's disease

Origin: The APOE2 targeted replacement mouse was developed in the laboratory of Nobuya Maeda at the University of North Carolina. The model was created by targeting the murine Apoe gene for replacement with the human APOE2 allele in E14TG2a ES cells and injecting the targeted cells into blastocysts. Resultant chimeras were backcrossed to C57BL/6 for seven generations (N7). Taconic received stock in 2000. The mice were backcrossed two additional times (N9) and embryo transfer derived. The colony is maintained through incrossing of homozygotes.

Color: Black

Wild type for Nnt mutation

Initial Publication: 
Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoe with human APOE*2. J Clin Invest, 102(1):130-5.

Animal Diet: NIH #31M Rodent Diet

Licensing Requirements:
Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic Farms, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred except to obtain embryos or fetuses required for research purposes
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.

Taconic Transgenic Models are produced in Isolated Barrier Unit (IBU™) facilities under MPF™ conditions, and shipped in Taconic Transit Cages (TTC™).


Related Publications

APOE2 Related Publications

Need additional help finding and ordering Taconic products and services?

Contact Us or call:

  • 888.TACONIC (822.6642)
  • Fax: 518.697.3910
  • +45 70 23 04 05 (Europe)